Clinical Trial Detail

NCT ID NCT03793179
Title Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Pembrolizumab + Pemetrexed Disodium

Pembrolizumab

Carboplatin + Pemetrexed Disodium

Age Groups: adult senior

Additional content available in CKB BOOST